Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
Description
Probenecid is an orally bioavailable, uricosuric agent that was first approved in 1951 for the treatment of gout, but was later found to have potent, broad-spectrum antiviral activity against several respiratory viruses including SARS-CoV-2. We
